Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on February 24, 2020, covering events occurring on February 20, 2020. The filing addresses corporate governance changes regarding the Board of Directors ahead of the 2020 Annual Meeting of Shareholders, expected to be held on May 5, 2020.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting specific corporate events under Item 5.02 and listing exhibits under Item 9.01.
Material Changes
- Board Composition: The number of directors is set to decrease to twelve effective as of the 2020 Annual Meeting of Shareholders.
- Director Departures: Mr. Michael Grobstein and Mr. Alan Lacy notified the company that they will not stand for re-election to the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The report is strictly procedural regarding the departure of directors and the adjustment of board size.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the May 5, 2020, Annual Meeting.
- Confirm the election results for any new directors intended to replace Mr. Grobstein and Mr. Lacy.
- Note that this filing does not impact the company's financial position or operational outlook.